Motor neurons, also called motoneurons, are the nerve cells that command muscles. Upper motor neurons have their cell bodies in the primary motor cortex of the brain and send their axons down to the brainstem and spinal cord. Lower motor neurons have their cell bodies in the ventral (anterior) horn of the spinal cord and in the motor nuclei of the cranial nerves in the brainstem, and their axons leave the central nervous system to reach the muscles.[1] A voluntary movement needs both: the upper motor neuron carries the command from the cortex, and the lower motor neuron carries it to the muscle.
Where are cell bodies of somatic motor neurons located?
The cell bodies of somatic motor neurons, the lower motor neurons that drive skeletal muscle, sit in the ventral horn of the spinal cord’s grey matter, or, for the muscles of the head and neck, in the cranial motor nuclei of the brainstem. They are large multipolar neurons with a crown of dendrites around the cell body. Each spinal motor axon leaves the ventral horn through the ventral nerve root and joins a spinal nerve. Because some axons must reach the foot, they can be a metre long, and their cell bodies are among the largest in the nervous system.[1] The ventral horns are widest in the lower cervical and lumbar segments, which control the many muscles of the arms and legs.[1]
The cell bodies of upper motor neurons sit in the primary motor cortex, in the precentral gyrus of the frontal lobe, arranged as a map of the body with the feet near the midline and the hand and face further out. The largest of them, the Betz cells, send their axons to lower motor neurons in the brainstem and spinal cord.[1]
These positions are set during embryonic development. Motor neurons differentiate from progenitor cells and gather into clusters called motor nuclei next to the floor plate of the brainstem and spinal cord, held in place by a balance of repulsive and attractive guidance signals.[2]
The Somatic Motor System
The somatic motor system controls skeletal muscle, the muscle under voluntary control. Its main route is the corticospinal tract, a chain of two neurons: the upper motor neuron in the motor cortex and the lower motor neuron in the ventral horn, which projects to the muscle.[1] A parallel route, the corticobulbar tract, carries commands from the motor cortex to the cranial motor nuclei in the brainstem.[1]
What are Nerve tracts?
A tract is a bundle of axons inside the brain or spinal cord; the same kind of bundle outside them is called a nerve.[3] The descending motor tracts are:[1]
- Lateral corticospinal tract. Its fibres cross to the other side at the pyramidal decussation in the lower medulla and run in the lateral column of the spinal cord. It controls the muscles of the arms and legs.
- Anterior corticospinal tract. Its fibres stay uncrossed in the medulla and cross at the spinal level where they end. It controls the muscles of the trunk, partly on both sides.
- Tectospinal tract. From the superior colliculus of the midbrain; postural movements driven by the superior colliculus.
- Reticulospinal tract. From the reticular formation of the brainstem; posture, locomotion and muscle tone of the trunk and proximal limbs.
- Vestibulospinal tract. From the vestibular nuclei; adjusts posture and balance using information from the inner ear.
- Rubrospinal tract. From the red nucleus of the midbrain; carries corrective commands driven by the cerebellum.
The tracts that do not pass through the pyramids of the medulla are grouped as the extrapyramidal system. The basal nuclei (basal ganglia) and the cerebellum do not send their own fibres to the muscles, but shape movement through these pathways: the basal nuclei help regulate the start of movement, and the cerebellum compares motor commands with feedback from the muscles and joints and corrects them.[1]
Types of Motor Neurons
Besides the division into upper and lower motor neurons, lower motor neurons that supply skeletal muscle come in three kinds, named after the conduction speed classes of their axons:[4]
| Type | Target | What it does |
|---|---|---|
| Alpha motor neuron | Ordinary (extrafusal) muscle fibres | Produces the force of contraction. Its large, myelinated axons conduct at about 70 to 120 m/s. |
| Gamma motor neuron | Fibres inside muscle spindles (intrafusal fibres), the stretch sensors of muscle | Supplies the small muscle fibres inside the spindle rather than the main muscle; its axons conduct in the slower A-gamma range. |
| Beta motor neuron | Both extrafusal and intrafusal fibres | Combines both roles; its axons conduct in the lower part of the alpha range. |
Visceral motor neurons are a separate group. The somatic system contracts skeletal muscle, while the autonomic nervous system controls cardiac muscle, smooth muscle and glands. It uses a two-neuron chain: a central neuron in the brainstem or the lateral horn of the spinal cord synapses on a neuron in an autonomic ganglion, which then reaches the target organ.[5]
Why Are Motor Neurons Important?
Motor neurons are the only route by which the nervous system can move the body. Every skeletal muscle fibre must be supplied by the axon terminal of a motor neuron to contract, and each fibre is supplied by only one motor neuron.[6] At the neuromuscular junction, the motor neuron releases acetylcholine, which binds nicotinic receptors on the muscle membrane and triggers contraction; the enzyme acetylcholinesterase then breaks it down.[7] If the lower motor neurons to a muscle die, nothing can make that muscle contract voluntarily.
The motor unit. One motor neuron and all the muscle fibres it supplies form a motor unit. In the muscles that move the eye, a motor neuron may supply only about six fibres, which allows very fine control; in the large muscles of the thigh and back, one motor neuron may supply thousands. Small motor units are recruited first, and larger ones are added as more force is needed.[6]
The length of motor neuron axons is also a weakness. Proteins and other cargo must be carried along the axon by motor proteins, and mutations that disrupt this axonal transport cause inherited forms of Charcot-Marie-Tooth disease, hereditary spastic paraplegia and motor neuron disease; motor neurons appear to be unusually vulnerable to such defects.[8]
What is Innervation?
Innervation is the supply of nerves to a part of the body. A muscle is innervated by the motor neurons whose axons reach it, each branching to contact its own group of muscle fibres at neuromuscular junctions.[6] Most muscles are also innervated by sensory neurons, which report muscle length and tension back to the spinal cord; this feedback, through spinal reflexes and the cerebellum, keeps movement smooth.[1] A muscle that loses its motor supply is said to be denervated: it becomes weak or paralysed, loses tone and reflexes, and its fibres may twitch.[9]
What are Dendrites?
Dendrites are the branching extensions of a neuron that receive signals from other neurons at synapses; information flows from the dendrites across the cell body to the axon.[10] A lower motor neuron’s dendrites collect input from upper motor neurons, from interneurons in the spinal cord and from sensory fibres, and the neuron fires when that input adds up to threshold. More on how neurons are built and signal is on our page on neurons and neurotransmitters.
Upper vs Lower Motor Neuron Signs
Because the two kinds of motor neuron fail in different ways, a neurological examination can usually tell which one is damaged.[9][11]
| Finding | Upper motor neuron damage | Lower motor neuron damage |
|---|---|---|
| Weakness | Yes, with slowed, poorly controlled movement | Yes; paralysis or partial loss of voluntary control (paresis) |
| Muscle tone | Kept or increased: spasticity, clasp-knife response | Reduced or lost: flaccid paralysis |
| Deep tendon reflexes | Strong (overactive) | Reduced or lost |
| Plantar response | Positive Babinski sign (toes extend) | No Babinski sign |
| Twitching and wasting | Not the typical signs | Fasciculations and fibrillation; muscles shrink (atrophy or wasting) |
| Other | Pronator drift |
Upper motor neuron damage occurs, for example, after a stroke, in cerebral palsy and in multiple sclerosis.[9]
Damaged Neurons & Dendrites in Neurodegenerative disease
Motor neuron diseases (MNDs) are a group of disorders in which motor neurons degenerate. The group includes amyotrophic lateral sclerosis (ALS), progressive bulbar palsy, primary lateral sclerosis, progressive muscular atrophy, spinal muscular atrophy, Kennedy’s disease and post-polio syndrome. They are classified by whether they are inherited or sporadic and by whether they affect upper motor neurons, lower motor neurons or both, and all cause muscle weakness that gradually worsens.[11]
ALS is not separate from MND: it is the most common type of motor neuron disease,[12] and it can affect both upper and lower motor neurons, causing rapid loss of muscle control and eventual paralysis.[11] Spinal muscular atrophy, by contrast, is a group of inherited diseases of lower motor neurons, most often caused by a missing or mutated SMN1 gene.[11]
Other common neurological diseases affect movement without being motor neuron diseases. Multiple sclerosis is a chronic inflammatory disease of the brain and spinal cord in which immune attack produces areas of demyelination, with varying loss of axons. After 10 to 20 years, many people develop a progressive course with impaired mobility and thinking, and no medication fully prevents or reverses that progression.[13] It damages the pathways of upper motor neurons among many others, but it is classed as a demyelinating disease. Parkinson’s disease mainly damages cells of the substantia nigra in the midbrain, not the motor neurons themselves.[7] The myelin side of this story is covered on our page on oligodendrocytes and myelination.
Motor Neuron Research and Cell Therapy Trials
Motor neurons in a dish. In 2008, researchers made induced pluripotent stem cells from an 82-year-old woman with an inherited form of ALS and turned them into motor neurons, the cell type the disease destroys.[14] Motor neurons made from stem cells are now used to study the disease: in one study, human motor neurons in culture were much more vulnerable to aggregates of the ALS-linked protein SOD1 than other cells in the same dish, even though they took up less of it.[15] The same approach is used to screen drugs. Ropinirole, a drug identified through screening with induced pluripotent stem cells, was tested in a phase 1/2a trial in 20 people with sporadic ALS: decline on the ALS functional rating scale did not differ from placebo during the 24-week double-blind period, the open-label extension reported slower decline, but the authors note the small numbers and many dropouts, so this needs confirmation.[16] In animal experiments, a short peptide injected into muscle was carried back along motor axons into spinal cord motor neurons, a possible route for delivering drugs.[17]
Cell therapy trials in ALS. The largest randomized trial of a cell therapy in ALS gave the patients’ own mesenchymal stem cells, treated to release extra growth factors (MSC-NTF), into the spinal fluid. In this phase 3, placebo-controlled trial, 196 people were randomized and 189 treated; 33% on the cells and 28% on placebo met the response criteria at 28 weeks, so the primary endpoint was not met.[18] Neural stem cells injected directly into the spinal cord were safe in phase 1 and 2 trials but did not change the rate of decline compared with historical controls.[19] A 2022 review of ALS concluded that stem cells are safe and well tolerated, but that apart from a possible transient positive effect, trials have failed to show long-lasting benefit.[20] As of November 2026, the US Food and Drug Administration list of approved cellular and gene therapy products includes no cell therapy for ALS or any other motor neuron disease. It does include gene therapies for spinal muscular atrophy caused by SMN1 mutations: onasemnogene abeparvovec, sold as ZOLGENSMA for children under 2 years and, for intrathecal use, as ITVISMA for patients aged 2 and older.[21][22][23] Drugs approved in the United States for ALS include riluzole, which lengthened the time to tracheostomy or death compared with placebo in its controlled trial,[24] and edaravone.[25] Tofersen is approved for ALS caused by SOD1 mutations under accelerated approval, based on a fall in plasma neurofilament light chain; in its main trial the difference in the ALS functional rating scale was not statistically significant, and continued approval depends on confirmatory trials.[26] Transplant trials of neural cells by condition are set out on our page on neural stem cells and glial cells, and the separate question of whether the adult brain makes new neurons on our page on neurogenesis.
Published Clinical Citations
[1] ^ Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e. Section 14.3, Motor Responses. OpenStax, Rice University; 2022. https://openstax.org/books/anatomy-and-physiology-2e/pages/14-3-motor-responses
[2] ^ Kim M, Bjorke B, Mastick GS. Motor neuron migration and positioning mechanisms: new roles for guidance cues. Seminars in Cell & Developmental Biology. 2019;85:78-83. https://doi.org/10.1016/j.semcdb.2017.11.016
[3] ^ Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e. Section 12.1, Basic Structure and Function of the Nervous System. OpenStax, Rice University; 2022. https://openstax.org/books/anatomy-and-physiology-2e/pages/12-1-basic-structure-and-function-of-the-nervous-system
[4] ^ Manzano GM, Giuliano LM, Nóbrega JA. A brief historical note on the classification of nerve fibers. Arquivos de Neuro-Psiquiatria. 2008;66(1):117-119. https://doi.org/10.1590/s0004-282×2008000100033
[5] ^ Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e. Section 15.1, Divisions of the Autonomic Nervous System. OpenStax, Rice University; 2022. https://openstax.org/books/anatomy-and-physiology-2e/pages/15-1-divisions-of-the-autonomic-nervous-system
[6] ^ Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e. Section 10.4, Nervous System Control of Muscle Tension. OpenStax, Rice University; 2022. https://openstax.org/books/anatomy-and-physiology-2e/pages/10-4-nervous-system-control-of-muscle-tension
[7] ^ Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e. Section 12.5, Communication Between Neurons. OpenStax, Rice University; 2022. https://openstax.org/books/anatomy-and-physiology-2e/pages/12-5-communication-between-neurons
[8] ^ Holzbaur EL. Motor neurons rely on motor proteins. Trends in Cell Biology. 2004;14(5):233-240. https://doi.org/10.1016/j.tcb.2004.03.009
[9] ^ Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e. Section 16.4, The Sensory and Motor Exams. OpenStax, Rice University; 2022. https://openstax.org/books/anatomy-and-physiology-2e/pages/16-4-the-sensory-and-motor-exams
[10] ^ Betts JG, Young KA, Wise JA, et al. Anatomy and Physiology 2e. Section 12.2, Nervous Tissue. OpenStax, Rice University; 2022. https://openstax.org/books/anatomy-and-physiology-2e/pages/12-2-nervous-tissue
[11] ^ National Institute of Neurological Disorders and Stroke. Motor Neuron Diseases. Last reviewed 13 March 2026. https://www.ninds.nih.gov/health-information/disorders/motor-neuron-diseases
[12] ^ NHS. Motor neurone disease. Page last reviewed 19 February 2025. https://www.nhs.uk/conditions/motor-neurone-disease/
[13] ^ Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. New England Journal of Medicine. 2018;378(2):169-180. https://doi.org/10.1056/NEJMra1401483
[14] ^ Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008;321(5893):1218-1221. https://doi.org/10.1126/science.1158799
[15] ^ Benkler C, O’Neil AL, Slepian S, et al. Aggregated SOD1 causes selective death of cultured human motor neurons. Scientific Reports. 2018;8(1):16393. https://doi.org/10.1038/s41598-018-34759-z
[16] ^ Morimoto S, Takahashi S, Ito D, et al. Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell. 2023;30(6):766-780.e9. https://doi.org/10.1016/j.stem.2023.04.017
[17] ^ Sellers DL, Bergen JM, Johnson RN, et al. Targeted axonal import (TAxI) peptide delivers functional proteins into spinal cord motor neurons after peripheral administration. Proceedings of the National Academy of Sciences of the USA. 2016;113(9):2514-2519. https://doi.org/10.1073/pnas.1515526113
[18] ^ Cudkowicz ME, Lindborg SR, Goyal NA, et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle & Nerve. 2022;65(3):291-302. https://doi.org/10.1002/mus.27472
[19] ^ Glass JD, Hertzberg VS, Boulis NM, et al. Transplantation of spinal cord-derived neural stem cells for ALS: analysis of phase 1 and 2 trials. Neurology. 2016;87(4):392-400. https://doi.org/10.1212/WNL.0000000000002889
[20] ^ Feldman EL, Goutman SA, Petri S, et al. Amyotrophic lateral sclerosis. Lancet. 2022;400(10360):1363-1380. https://doi.org/10.1016/S0140-6736(22)01272-7
[21] ^ US Food and Drug Administration. Approved Cellular and Gene Therapy Products. Content current as of 30 October 2026. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
[22] ^ US Food and Drug Administration. ZOLGENSMA (onasemnogene abeparvovec-xioi) prescribing information, BLA 125694; label effective 16 June 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68cd4f06-70e1-40d8-bedb-609ec0afa471
[23] ^ US Food and Drug Administration. ITVISMA (onasemnogene abeparvovec-brve) prescribing information, BLA 125856; label effective 16 June 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab2e1c6c-4f95-4243-9296-1734e0a30591
[24] ^ US Food and Drug Administration. Riluzole tablets prescribing information (Sun Pharmaceutical Industries), ANDA 091417. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4c851be4-f0d0-4b24-baf9-427ddfc6f7b0
[25] ^ US Food and Drug Administration. RADICAVA and RADICAVA ORS (edaravone) prescribing information, NDA 215446; label effective 5 May 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0ce2c1c4-2a40-485c-b7cb-96a9b85d9d11
[26] ^ US Food and Drug Administration. QALSODY (tofersen) prescribing information, NDA 215887; label effective 23 October 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81356b45-1cb7-4eef-88ea-e44cc18b47c5